L’Orée des Mas
Bât. Les Cyprès Avenue du Golf Baillargues
Montpellier 34670
France
33 4 67 03 03 96
https://www.medesispharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 10
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Jean-Claude Maurel M.D., MHB | CEO, President & Member of Management Board | S.O. | S.O. | S.O. |
Ms. Tessa Olivato | Member of the Executive Board and Director of Administrative & Financial | S.O. | S.O. | S.O. |
Mr. Alexandre Lemoalle | Director of Strategic Partnerships & Member of the Executive Board | S.O. | S.O. | S.O. |
Ms. Solene Guilliot | Member of the Executive Board and Director of Medical Affairs & Clinical Development | S.O. | S.O. | S.O. |
Mr. Mario Alcaraz | Member of the Executive Board & General Secretary | S.O. | S.O. | S.O. |
Medesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and is based in Montpellier, France.
L’ISS Governance QualityScore de Medesis Pharma S.A. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..